코로나바이러스감염증-19에서의 회복기혈장치료 시 고려사항 = Practical Considerations in Convalescent Plasma Therapy for Coronavirus Disease 2019

다국어 초록 (Multilingual Abstract)

Convalescent plasma therapy has been used to achieve passive immunization against diverse infectious agents by administering pathogen-specific antibodies. Coronavirus disease 19 (COVID-19), which originated in Wuhan, China, has recently become a major concern all over the world. There are no specific treatment recommendations for COVID-19 because of the lack of knowledge and evidence about this virus. Convalescent plasma therapy can be used as an empirical and investigational treatment for COVID-19, and so we briefly describe the main issues related to convalescent plasma therapy from the perspective of transfusion medicine. (Korean J Blood Transfus 2020;31:67-69)

참고문헌 (Reference)

1 World Health Organization, "Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks: interim guidance for national health authorities and blood transfusion services, version 1.0 September 2014"

2 Cheng Y, "Use of convalescent plasma therapy in SARS patients in Hong Kong" 24 : 44-46, 2005

3 U.S. Food & Drug Administration, "Updated information for blood establishments regarding the novel Coronavirus outbreak"

4 Chenguang Shen, "Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma" American Medical Association (AMA) 323 (323): 1582-, 2020

5 Ko JH, "Serologic responses of 42MERS-coronavirus-infected patients according to the disease severity" 89 : 106-111, 2017

6 U.S. Food and Drug Administration, "Recommendations for investigational COVID-19 convalescent plasma"

7 Park WB, "Kinetics of serologic responses to MERS Coronavirus infection in humans, South Korea" 21 : 2186-2189, 2015

8 Arabi YM, "Feasibility of using convalescent plasma immunotherapy for MERSCoV infection, Saudi Arabia" 22 : 1554-1561, 2016

9 Chen L, "Convalescent plasma as a potential therapy for COVID-19" 20 : 398-400, 2020

10 van Griensven J, "Convalescent plasma and the dose of Ebola virus antibodies" 376 : 1297-, 2017

11 Marano G, "Convalescent plasma : new evidence for an old therapeutic tool" 14 : 152-157, 2016

12 Joint United Kingdom (UK) Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee, "Conoravirus infection in donor selection guideline-Whole blood edition 203, release 48"

13 Min CK, "Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity" 6 : 25359-, 2016

14 Ko JH, "Challenges of convalescent plasma infusion therapy in Middle East respiratory Coronavirus infection : a single centre experience" 23 : 617-622, 2018